tango therapeutics - TNGX
TNGX
Close Chg Chg %
2.94 0.16 5.44%
Closed Market
3.10
+0.16 (5.44%)
Volume: 2.82M
Last Updated:
Dec 20, 2024, 4:00 PM EDT
Company Overview: tango therapeutics - TNGX
TNGX Key Data
| Open $2.91 | Day Range 2.80 - 3.13 |
| 52 Week Range 2.70 - 13.00 | Market Cap $315.81M |
| Shares Outstanding 107.42M | Public Float 49.52M |
| Beta 0.75 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.17 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.60M |
TNGX Performance
| 1 Week | 1.31% | ||
| 1 Month | -20.92% | ||
| 3 Months | -62.65% | ||
| 1 Year | -69.06% | ||
| 5 Years | N/A |
TNGX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About tango therapeutics - TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
TNGX At a Glance
Tango Therapeutics, Inc.
201 Brookline Avenue
Boston, Massachusetts 02215
| Phone | 1-857-320-4900 | Revenue | 36.53M | |
| Industry | Biotechnology | Net Income | -101,744,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 46.931% | |
| Fiscal Year-end | 12 / 2024 | Employees | 140 | |
| View SEC Filings |
TNGX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 25.632 |
| Price to Book Ratio | 3.998 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.704 |
| Enterprise Value to Sales | 17.451 |
| Total Debt to Enterprise Value | 0.061 |
TNGX Efficiency
| Revenue/Employee | 260,907.143 |
| Income Per Employee | -726,742.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.084 |
TNGX Liquidity
| Current Ratio | 7.544 |
| Quick Ratio | 7.544 |
| Cash Ratio | 7.352 |
TNGX Profitability
| Gross Margin | 93.388 |
| Operating Margin | -312.572 |
| Pretax Margin | -278.178 |
| Net Margin | -278.545 |
| Return on Assets | -23.442 |
| Return on Equity | -40.488 |
| Return on Total Capital | -34.84 |
| Return on Invested Capital | -35.158 |
TNGX Capital Structure
| Total Debt to Total Equity | 15.377 |
| Total Debt to Total Capital | 13.327 |
| Total Debt to Total Assets | 9.344 |
| Long-Term Debt to Equity | 14.554 |
| Long-Term Debt to Total Capital | 12.615 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Tango Therapeutics - TNGX
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 37.04M | 24.86M | 36.53M | |
Sales Growth
| - | - | -32.89% | +46.93% | - |
Cost of Goods Sold (COGS) incl D&A
| - | 1.97M | 4.03M | 2.42M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | 1.97M | 4.03M | 2.42M | |
Depreciation
| - | 1.97M | 4.03M | 2.42M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | +104.88% | -40.04% | - |
Gross Income
| - | 35.08M | 20.83M | 34.11M | |
Gross Income Growth
| - | - | -40.61% | +63.75% | - |
Gross Profit Margin
| - | +94.69% | +83.80% | +93.39% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 148.87K | 93.27M | 131.90M | 148.28M | |
Research & Development
| - | 77.64M | 105.91M | 115.20M | |
Other SG&A
| 148.87K | 15.63M | 26.00M | 33.09M | |
SGA Growth
| - | +62,551.40% | +41.43% | +12.42% | |
Other Operating Expense
| - | - | - | 32.56K | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (181.42K) | (58.19M) | (111.07M) | (114.17M) | |
Non Operating Income/Expense
| 65.25K | 247.00K | 2.95M | 12.56M | |
Non-Operating Interest Income
| 65.25K | 495.00K | 1.46M | 6.62M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (116.18K) | (57.94M) | (108.12M) | (101.61M) | |
Pretax Income Growth
| - | -49,772.61% | -86.60% | +6.02% | |
Pretax Margin
| - | -156.43% | -434.92% | -278.18% | |
Income Tax
| 6.86K | 292.00K | 54.00K | 134.00K | |
Income Tax - Current - Domestic
| - | - | - | 6.86K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (123.05K) | (58.23M) | (108.18M) | (101.74M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (123.05K) | (58.23M) | (108.18M) | (101.74M) | |
Net Income Growth
| - | -47,227.83% | -85.76% | +5.95% | |
Net Margin Growth
| - | -157.21% | -435.14% | -278.54% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (123.05K) | (58.23M) | (108.18M) | (101.74M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (123.05K) | (58.23M) | (108.18M) | (101.74M) | |
EPS (Basic)
| -0.0058 | -0.9376 | -1.2318 | -1.0758 | |
EPS (Basic) Growth
| - | -16,065.52% | -31.38% | +12.66% | |
Basic Shares Outstanding
| 21.38M | 62.11M | 87.82M | 94.57M | |
EPS (Diluted)
| -0.0058 | -0.9376 | -1.2318 | -1.0758 | |
EPS (Diluted) Growth
| - | -16,065.52% | -31.38% | +12.66% | |
Diluted Shares Outstanding
| 21.38M | 62.11M | 87.82M | 94.57M | |
EBITDA
| (181.42K) | (56.22M) | (107.04M) | (111.76M) | |
EBITDA Growth
| - | -30,891.07% | -90.39% | -4.40% | |
EBITDA Margin
| - | -151.78% | -430.58% | -305.96% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 12.50 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.338 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -1.201 | |
| Last Quarter’s Earnings | -0.27 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.08 | Next Fiscal Year Estimate | -1.425 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 5 | 10 | 10 |
| Mean Estimate | -0.34 | -0.36 | -1.20 | -1.43 |
| High Estimates | -0.25 | -0.29 | -1.11 | -1.21 |
| Low Estimate | -0.37 | -0.46 | -1.26 | -1.54 |
| Coefficient of Variance | -11.05 | -17.22 | -3.52 | -7.19 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 8 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Tango Therapeutics - TNGX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Tango Therapeutics - TNGX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 8, 2024 | Boxer Capital LLC | 3,610,642 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $3.14 per share | 11,337,415.88 |
| Jul 25, 2024 | Third Rock Ventures LLC | 18,197,074 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.78 per share | 177,967,383.72 |
| Jul 25, 2024 | Third Rock Ventures LLC | 18,072,074 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.79 per share | 176,925,604.46 |
| Jul 3, 2024 | Tavistock Life Sciences Co. (Investment Management) | 314,524 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.57 per share | 2,695,470.68 |
| Jul 3, 2024 | Tavistock Life Sciences Co. (Investment Management) | 203,793 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.87 per share | 1,807,643.91 |
| Jul 3, 2024 | Tavistock Life Sciences Co. (Investment Management) | 108,793 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.68 per share | 944,323.24 |
| Feb 9, 2024 | Daniella Beckman Chief Financial Officer | 134,214 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.56 per share | 1,685,727.84 |
| Feb 9, 2024 | Daniella Beckman Chief Financial Officer | 132,397 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.62 per share | 1,670,850.14 |
| Feb 9, 2024 | Barbara L. Weber Chief Executive Officer; Director | 1,539,624 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.56 per share | 19,337,677.44 |
| Feb 9, 2024 | Barbara L. Weber Chief Executive Officer; Director | 1,535,167 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.62 per share | 19,373,807.54 |
| Feb 9, 2024 | Douglas John Barry General Counsel | 45,335 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.56 per share | 569,407.60 |
| Feb 9, 2024 | Douglas John Barry General Counsel | 43,981 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.62 per share | 555,040.22 |
| Feb 9, 2024 | Adam S. Crystal See Remarks | 123,561 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.56 per share | 1,551,926.16 |
| Feb 9, 2024 | Adam S. Crystal See Remarks | 119,478 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.62 per share | 1,507,812.36 |